ValoreQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25TTMSpese di vendita, generali e amministrative57.3 M49.04 M43.28 M44.95 M46.01 M183.29 MRicerca e sviluppo76.38 M70.92 M53.37 M69.35 M50.13 M243.77 MReddito operativo-103.61 M-88.97 M-65.54 M-90.02 M-70.75 M-315.28 MProventi non operativi, Totale-16.8 M-5.59 M4.73 M12.95 M-26.82 M-14.73 MOneri finanziari, al netto degli interessi capitalizzati31.37 M—————Proventi non operativi, esclusi gli oneri finanziari-43.91 M-3.69 M-229 K3.68 M-16.17 M-16.41 MEntrate/uscite straordinarie-4.25 M-1.9 M4.96 M9.26 M-10.64 M1.68 MUtile al lordo delle imposte-107.86 M-90.87 M-60.58 M-80.75 M-81.39 M-313.6 MQuota di utile0———0—Imposte-325 K88 K-283 K1 000-643 K-837 KInteressi di minoranza0—————Altri proventi/oneri al netto delle imposte-569 K-149 K103 K-1.56 M-453 K-2.06 MUtile netto al lordo delle attività cessate-107.53 M-90.96 M-60.3 M-80.75 M-80.75 M-312.76 MAttività cessate——————Utile netto-107.53 M-90.96 M-60.3 M-80.75 M-80.75 M-312.76 MRegolazione della diluizione——————Dividendi privilegiati——————Utile netto diluito attribuibile agli azionisti ordinari-106.86 M-90.96 M-60.3 M-80.75 M-80.75 M-312.76 MUtile base per azione (EPS base)-1.92-1.68-1.1-1.45-1.41-5.64Utile diluito per azione (EPS diluito)-1.91-1.68-1.1-1.45-1.41-5.64Numero medio di azioni ordinarie in circolazione51.89 M54.24 M54.86 M55.63 M55.46 M220.19 MAzioni diluite in circolazione51.89 M54.24 M54.86 M55.63 M55.46 M220.19 MEBITDA-85.61 M-78.19 M-54.76 M-79.67 M-52.05 M-264.67 MEBIT-103.61 M-82.89 M-59.46 M-84.28 M-70.75 M-297.37 MCosto del fatturato——————Altri costi del venduto——————Ammortamento e svalutazione (liquidità)18 M4.7 M4.7 M4.6 M18.7 M32.7 M
Ginkgo Bioworks Holdings Inc Class A
Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It raised $290 million in September and $350 million in October of that year. Ginkgo Bioworks went public on the New York Stock Exchange via a SPAC merger on September 17, 2021.